ReviewChinese journal of cancer2015

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.

Fei Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.